Dr Michael Moore pursued an academic research career in a major UK cancer centre prior to entering the Life Sciences industry. He holds PhD and DSc degrees from the University of Nottingham and is a Fellow of the Royal College of Pathologists.

He was CEO of Piramed Limited which was acquired by Roche, and subsequently over a period of 15 years has worked as a scientific consultant, served as founder chairman of two UK start-ups, and as a non-executive director of Trillium Therapeutics Inc. (acquired by Pfizer), and non-listed UK companies, including a previous term with Chronos.